Guardant Health Future Growth
Future criteria checks 1/6
Guardant Health is forecast to grow earnings and revenue by 24.9% and 17% per annum respectively. EPS is expected to grow by 27.5% per annum. Return on equity is forecast to be -216.4% in 3 years.
Key information
24.9%
Earnings growth rate
27.5%
EPS growth rate
| Healthcare earnings growth | 20.9% |
| Revenue growth rate | 17.0% |
| Future return on equity | -216.4% |
| Analyst coverage | Good |
| Last updated | 18 Nov 2024 |
Recent future growth updates
Recent updates
Market Participants Recognise Guardant Health, Inc.'s (NASDAQ:GH) Revenues Pushing Shares 36% Higher
Nov 08
An Intrinsic Calculation For Guardant Health, Inc. (NASDAQ:GH) Suggests It's 44% Undervalued
Oct 25Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?
Sep 24Guardant Health: Top-Line Growth Undeniable, Compounding Ability Remains Unseen
Aug 21Guardant Health, Inc.'s (NASDAQ:GH) P/S Is Still On The Mark Following 26% Share Price Bounce
Jul 31Guardant Health, Inc. (NASDAQ:GH) Shares Could Be 49% Below Their Intrinsic Value Estimate
Jul 12Guardant: Double-Digit Sales Projections Come At A Cost
Jun 06Is Now The Time To Look At Buying Guardant Health, Inc. (NASDAQ:GH)?
Jun 04Investors Appear Satisfied With Guardant Health, Inc.'s (NASDAQ:GH) Prospects As Shares Rocket 31%
May 14Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?
Mar 29With Guardant Health, Inc. (NASDAQ:GH) It Looks Like You'll Get What You Pay For
Jan 21Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?
Nov 20Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?
Sep 26A Look At The Fair Value Of Guardant Health, Inc. (NASDAQ:GH)
Sep 05Is Guardant Health (NASDAQ:GH) A Risky Investment?
Aug 15A Look At The Intrinsic Value Of Guardant Health, Inc. (NASDAQ:GH)
May 28Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?
Apr 05Is Guardant Health (NASDAQ:GH) Using Too Much Debt?
Dec 28Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,021 | -324 | -227 | -140 | 16 |
| 12/31/2025 | 848 | -377 | -264 | -186 | 22 |
| 12/31/2024 | 724 | -415 | -296 | -239 | 22 |
| 9/30/2024 | 692 | -512 | -274 | -254 | N/A |
| 6/30/2024 | 644 | -491 | -299 | -281 | N/A |
| 3/31/2024 | 604 | -461 | -301 | -281 | N/A |
| 12/31/2023 | 564 | -479 | -345 | -325 | N/A |
| 9/30/2023 | 536 | -432 | -363 | -337 | N/A |
| 6/30/2023 | 510 | -508 | -383 | -337 | N/A |
| 3/31/2023 | 482 | -665 | -418 | -355 | N/A |
| 12/31/2022 | 450 | -655 | -387 | -309 | N/A |
| 9/30/2022 | 431 | -606 | -388 | -296 | N/A |
| 6/30/2022 | 408 | -551 | -363 | -271 | N/A |
| 3/31/2022 | 391 | -419 | -309 | -221 | N/A |
| 12/31/2021 | 374 | -406 | -284 | -209 | N/A |
| 9/30/2021 | 344 | -409 | -249 | -191 | N/A |
| 6/30/2021 | 324 | -379 | -191 | -146 | N/A |
| 3/31/2021 | 298 | -336 | -143 | -107 | N/A |
| 12/31/2020 | 287 | -254 | -158 | -104 | N/A |
| 9/30/2020 | 271 | -185 | -129 | -75 | N/A |
| 6/30/2020 | 258 | -120 | -118 | -66 | N/A |
| 3/31/2020 | 245 | -77 | -102 | -56 | N/A |
| 12/31/2019 | 214 | -76 | -68 | -47 | N/A |
| 9/30/2019 | 184 | -76 | -60 | -43 | N/A |
| 6/30/2019 | 145 | -87 | -81 | -67 | N/A |
| 3/31/2019 | 111 | -97 | -89 | -70 | N/A |
| 12/31/2018 | 91 | -85 | -92 | -72 | N/A |
| 9/30/2018 | 78 | -75 | -85 | -64 | N/A |
| 6/30/2018 | 67 | -84 | N/A | -68 | N/A |
| 3/31/2018 | 57 | -83 | N/A | -65 | N/A |
| 12/31/2017 | 50 | -89 | N/A | -72 | N/A |
| 12/31/2016 | 25 | -46 | N/A | -37 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GH is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GH is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GH is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GH's revenue (17% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: GH's revenue (17% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GH is forecast to be unprofitable in 3 years.